About Spruce Biosciences
Spruce Biosciences is a company based in San Francisco (United States) founded in 2014 by Alexis Howerton.. Spruce Biosciences has raised $108 million across 3 funding rounds from investors including Citadel, Abingworth and 5AM Ventures. The company has 15 employees as of December 31, 2022. Spruce Biosciences offers products and services including TA-ERT. Spruce Biosciences operates in a competitive market with competitors including MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Sigilon, among others.
- Headquarter San Francisco, United States
- Employees 15 as on 31 Dec, 2022
- Founders Alexis Howerton
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Spruce Biosciences, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$108 M (USD)
in 3 rounds
-
Latest Funding Round
$53.62 M (USD), Post-IPO
Feb 09, 2023
-
Investors
Citadel
& 10 more
-
Employee Count
15
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Spruce Biosciences
Spruce Biosciences is a publicly listed company on the NASDAQ with ticker symbol SPRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Spruce Biosciences
Spruce Biosciences offers a comprehensive portfolio of products and services, including TA-ERT. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets Mucopolysaccharidosis Type IIIB to improve neurological outcomes.
Unlock access to complete
Unlock access to complete
Funding Insights of Spruce Biosciences
Spruce Biosciences has successfully raised a total of $108M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $53.62 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $53.6M
-
First Round
First Round
(01 Jun 2016)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2023 | Amount | Post-IPO - Spruce Biosciences | Valuation |
investors |
|
| Feb, 2020 | Amount | Series B - Spruce Biosciences | Valuation | Omega Funds , Abingworth | |
| Jun, 2016 | Amount | Series A - Spruce Biosciences | Valuation | Novo Holdings |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Spruce Biosciences
Spruce Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Abingworth and 5AM Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Spruce Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Spruce Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Spruce Biosciences Comparisons
Competitors of Spruce Biosciences
Spruce Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MBX Biosciences, Amolyt Pharma, OMass Therapeutics, Spruce and Sigilon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Spruce is engaged in providing real estate closing services.
|
|
| domain | founded_year | HQ Location |
Therapeutics for chronic diseases are developed via cell engineering platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Spruce Biosciences
Frequently Asked Questions about Spruce Biosciences
When was Spruce Biosciences founded?
Spruce Biosciences was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Spruce Biosciences located?
Spruce Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Spruce Biosciences?
Richard King is the current CEO of Spruce Biosciences.
Is Spruce Biosciences a funded company?
Spruce Biosciences is a funded company, having raised a total of $108M across 3 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Jun 01, 2016.
How many employees does Spruce Biosciences have?
As of Dec 31, 2022, the latest employee count at Spruce Biosciences is 15.
What does Spruce Biosciences do?
Spruce Biosciences was founded in 2014 and is based in San Francisco, United States. As a clinical-stage biopharmaceutical company, small molecule therapeutics are developed for rare endocrine disorders impacting the hypothalamic-pituitary-adrenal axis. The lead program, SPR001, addresses congenital adrenal hyperplasia in both chronic and acute forms and is advancing through Phase 2 clinical trials. The mechanism of action for this oral candidate remains under investigation.
Who are the top competitors of Spruce Biosciences?
Spruce Biosciences's top competitors include MBX Biosciences, OMass Therapeutics and Spruce.
What products or services does Spruce Biosciences offer?
Spruce Biosciences offers TA-ERT.
Is Spruce Biosciences publicly traded?
Yes, Spruce Biosciences is publicly traded on NASDAQ under the ticker symbol SPRB.
Who are Spruce Biosciences's investors?
Spruce Biosciences has 11 investors. Key investors include Citadel, Abingworth, 5AM Ventures, Healthcap, and Novo Holdings.
What is Spruce Biosciences's ticker symbol?
The ticker symbol of Spruce Biosciences is SPRB on NASDAQ.